Proteins and Peptides
24 November 2015
Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A23 November 2015
BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions22 November 2015
Angiochem Reports Positive Clinical Data with ANG1005 in Breast Cancer Patients with Leptomeningeal Carcinomatosis20 November 2015
European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma19 November 2015
Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program18 November 2015
Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by the FDA17 November 2015
Cidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results17 November 2015
European Medicines Agency approves Xiapex® for concurrent treatment of palpable cords14 November 2015
Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss14 November 2015
Baxalta Gains EU Marketing Authorization to Provide OBIZUR to Adult Patients with Acquired Haemophilia A14 November 2015
Baxalta to Advance Care for Hemophilia A Patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds13 November 2015
Derma Sciences Announces Results of Futility Analyses for Phase 3 Clinical Trials of Aclerastide in Diabetic Foot Ulcer Healing13 November 2015
Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week10 November 2015
Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association (AHA) Conference 20159 November 2015
PhaseBio Announces Initiation of Phase 2a Multiple Ascending Dose Study of Once-Weekly Basal Insulin PE0139 in Type 2 Diabete9 November 2015
Preliminary Phase I Results Demonstrate Potential Utility of DARPins in Anticancer Treatment7 November 2015
Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity3 November 2015
Proteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational VonapanitaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports